Tyrosine kinase inhibitors are oral targeted therapies that block the signalling enzymes cancer cells use to grow and divide. Imatinib was the first, turning chronic myeloid leukaemia from a fatal disease into a manageable one and proving that targeting a specific molecular driver could work. Later TKIs hit different kinases — or several at once — which is why they are used across leukaemias, kidney, liver and thyroid cancers.
Class descriptions are written by the Priya Life Science editorial team. Individual drug pages combine that summary with live label, approval, manufacturer and shortage data from the U.S. FDA via the openFDA API. This page is general information and is not medical advice — it is not exhaustive, drugs within a class are not automatically interchangeable, and approvals and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions. Always consult the official prescribing information and your clinician or pharmacist. Related: Drug Shortages Tracker · FDA Approvals · All drug comparisons